MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD

Experimental Cell Research

Volumn 320, Issue 1, 2014, Pages 12-20

  Chen, Yiran ^a,b   Ke, Guihao ^a   Han, Duo ^c   Liang, Shanhui ^a   Yang, Gong ^a   Wu, Xiaohua ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b CANCER HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cervical cancer; Chemotherapy; Cisplatin; MiR 181a; PRKCD

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 181A; PRKCD PROTEIN; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CERVICAL SQUAMOUS CELL CARCINOMA; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CARCINOMA;

MUS MUSCULUS;

EID: 84888204275     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.10.014     Document Type: Article

References (28)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
2. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340:1144-1153.
3. Eifel P.J. Concurrent chemotherapy and radiation: A major advance for women with cervical cancer. J. Clin. Oncol. 1999, 17:1334-1335.
4. Green J., Kirwan J., Tierney J., et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst. Rev. 2005, 20(3):CD002225.
5. Tambaro R., Scambia G., Di Maio M., et al. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit. Rev. Oncol. Hematol. 2004, 52(1):33-44.
6. Dueñas-González A., Zarbá J.J., Patel F., et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J. Clin. Oncol. 2011, 29(13):1678-1685.
7. Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409:363-366.
8. Sevignani C., Calin G.A., Siracusa L.D., Croce C.M. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm. Genome 2006, 17:189-202.
9. Zhang B., Wang Q., Pan X. MicroRNAs and their regulatory roles in animals and plants. J. Cell. Physiol. 2007, 210:279-289.
10. Iorio M.V., Croce C.M. MicroRNA involvement in human cancer. Carcinogenesis 2012, 33:1126-1133.
11. Meng F., Henson R., Lang M., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
12. Yang H.u.a., Kong William, He Lili MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68:425-433.
13. Ke G., Liang L., Yang J.M., et al. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene 2013, 32:3019-3027.
14. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
15. Panda H., Chuang T.D., Luo X., Chegini N. Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3. J. Clin. Endocrinol. Metab. 2012, 97:E1316-E1326.
16. Fei J., Li Y., Zhu X., Luo X. miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS One 2012, 7:e32834.
17. Galluzzi L., Morselli E., Vitale I., et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70:1793-1803.
18. Qamar L., Davis R., Anwar A., Behbakht K. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Gynecol. Oncol. 2008, 110:425-431.
19. Mohanty S., Huang J., Basu A. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1. Clin. Cancer Res. 2005, 11:6730-6737.
20. Clark A.S., West K.A., Blumberg P.M., Dennis P.A. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003, 63:780-786.
21. Sumitomo M., Asano T., Asakuma J., Asano T., Nanus D.M., Hayakawa M. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin. Cancer Res. 2004, 10:260-266.
22. Basu A., Akkaraju G.R. Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C. Biochemistry 1999, 38:4245-4251.
23. Blass M., Kronfeld I., Kazimirsky G., Blumberg P.M., Brodie C. Tyrosine phosphorylation of protein kinase Cδ is essential for its apoptotic effect in response to etoposide. Mol. Cell Biol. 2002, 22:182-195.
24. Basu A., Woolard M.D., Johnson C.L. Involvement of protein kinase C-δ in DNA damage-induced apoptosis. Cell Death Differ. 2001, 8:899-908.
25. Iioka Y., Mishima K., Azuma N., et al. Overexpression of protein kinase Cdelta enhances cisplatin-induced cytotoxicity correlated with p53 in gastric cancer cell line. Pathobiology 2005, 72(3):152-159.
26. Basu A., Evans R.W. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). Int. J. Cancer 1994, 58:587-591.
27. Watanabe T., Ono Y., Taniyama Y., et al. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-subspecies. Proc. Natl. Acad. Sci. USA 1992, 89:10159-10163.
28. Lu Z., Hornia A., Jiang Y.W., Zang Q., Ohno S., Foster D.A. Tumor promotion by depleting cells of protein kinase C. Mol. Cell Biol. 1997, 17:3418-3428.